- Cardinal Health invites independent pharmacy owners to ‘discover new horizons’ at RBC 2013
- Facing pharmacy trends for the remainder of the year
- MedFolio launches electronic pillbox to improve patient adherence
- Kathleen Sebelius cites pharmacists' importance as Rite Aid CEO introduces Obamacare resource program
- Walgreens Infusion Services can save $10.8 million in healthcare costs annually
NEW YORK — A new bill in Florida's state legislature would allow pharmacists to substitute biosimilars for branded biotech drugs, according to published reports.
The Sarasota Herald-Tribune reported that the Health Quality Subcommittee of the Florida House of Representatives approved a bill that would allow for substitution while requiring pharmacists to notify prescribing physicians within five days and require the doctor and pharmacist to maintain a record for at least four years.
The Patient Protection and Affordable Care Act included a regulatory approval pathway for biosimilars, though the Food and Drug Administration has yet to finalize regulations for them.